Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ICSeaStar Medical Holding Corporation logo

SeaStar Medical Holding Corporation (ICU)

NASDAQ Capital Market · Currency in USD
$2.41 ▼ -0.44 (-15.44%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.42 ▲ +0.01 (+0.41%)
After hours: Oct 23, 7:33 PM ET

Summary

Previous Close
$2.85
Open
$2.87
Day's Range
$2.40 – $2.98
52 Week Range
$2.07 – $6.14
Volume
340,096
Avg. Volume
116,475
Market Cap
$6.84M
Beta (5Y Monthly)
-1.07
PE Ratio (TTM)
--
EPS (TTM)
-$3.34
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$8.00

Profile: SeaStar Medical Holding Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
18
CEO
Eric Schlorff

SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.95 · Revenue est. $500.00K
DateEst.Actual
Aug 12, 2026-$0.97-$0.91Beat
May 13, 2026-$0.73-$0.90Miss
Mar 25, 2026-$0.97-$0.80Beat
Nov 13, 2025-$1.50-$1.30Beat
Aug 13, 2025-$4.30-$1.80Beat
May 14, 2025-$5.20-$4.40Beat

Analyst view

Consensus price target
$8.00 ▲ +232.0%
Range $8.00 – $8.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ICU and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.